FraserCG. Analytical goals for glucose analyses. Ann Clin Biochem1986; 23: 379–89.
4.
BrowningMCK. Analytical goals for quantities used to assess thyrometabolic status. Ann Clin Biochem1989; 26: 1–12.
5.
HarrisEK. Statistical principles underlying analytic goal-setting in clinical chemistry. Am J Clin Pathol1979; 72: 374–82.
6.
FraserCG. The application of theoretical goals based on biological variation data in proficiency testing. Arch Pathol Lab Med1988; 112: 404–15.
7.
TonksDB. A study of the accuracy and precision of clinical chemistry determinations in 170 Canadian laboratories. Clin Chem1963; 9: 217–23.
8.
GlickJH. Expression of random analytical error as a percentage of the range of clinical interest. Clin Chem1976; 22: 475–83.
9.
BurnettDAyersGJ. Quality control of drug assay. In: RichensAMarksV, eds. Therapeutic Drug Monitoring. Edinburgh: Churchill Livingstone, 1981; 183–200.
10.
PenryJK. Reliability of serum antiepileptic drug concentrations and patient management. In: PippengerCEPenryJKKuttH, eds. Antiepileptic Drugs: Quantitative Analysis and Interpretation. New York: Raven Press, 1978; 1.
11.
FraserCG. Desirable standards of performance for therapeutic drug monitoring. Clin Chem1987; 33: 387–9.
HalkinHMazarAAlmogSSchnapsY.Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation. Eur J Clin Pharmacol1982; 23: 255–8.
20.
FraserCGLipworthBJ. More on analytical goals for theophylline assays. Clin Chem1988; 34: 796–7.
21.
TaylorWJFinnALGotcherS, eds. Individualizing Drug Therapy. Clinical Notes on the Application of Drug Monitoring. New York: Gross, Townsend, Frank, 1981.
22.
Higgins T, Goals for TDM: A correction. Clin Chem1987; 33: 1298.
23.
United Kingdom External Quality Schemes Annual Report for 1987. London: DHSS, 1988.
24.
RoweDJFWatsonIDWilliamsJBerryDJ. The clinical use of measurement of theophylline. Ann Clin Biochem1988; 25, 4–26.
25.
PenberthyLA. Summary of results from the eleventh cycle of the RCPA-AACB general serum chemistry quality assurance programme. Clin Biochem Rev1987; 8: 30–41.
PenberthyLA. Summary of results from the fourteenth cycle of the RCPA-AACB general serum chemistry quality assurance programme. Clin Biochem Rev1988; 9: 20–30.
28.
StewartMJWatsonID. Analytical reviews in clinical chemistry: Methods for the estimation of salicylate and paracetamol in serum, plasma and urine. Ann Clin Biochem1987; 24: 552–65.
29.
BedfordCCummingsAJMartinBK. A kinetic study of the elimination of salicylate in man. Br J Pharmacol1965; 24: 418–31.
30.
PrescottLFBalali-MoodMCritchleyJAJHDiuresis or urinary alkalinisation for salicylate poisoning. Br Med J1982; 285: 1383–5.
31.
FraserCGBrowningMCK. Deciding the optimum interval between specimens collections: Theory and nomograms. Clin Chem1987; 33: 1436–8.
32.
FaridYYZWatsonIDStewartMJ. An assay for methotrexate and its metabolites in serum and urine by ion pair HPLC. J Pharm Biomed Anal1983; 1: 55–63.
33.
StewartMJ. Drug analyses in poisoned patients, the need to be specific. Ann Clin Biochem1982; 19: 254–7.
34.
HallworthMJ. Audit of therapeutic drug monitoring. Ann Clin Biochem1988; 25: 121–8.
35.
StewartMJWatsonID. Standard units for expressing drug concentrations in biological fluids. Br J Clin Pharmacol1983; 16: 3–7.
36.
RatcliffeJGWorthHGJ. Units for drug concentrations in biological fluids. Lancet1986; i: 202.
37.
Council on Scientific Affairs. SI Units for the clinical laboratory. JAMA1985; 253: 2553–5.